Roots Analysis has announced the addition of “Allogeneic Cell Therapy Market, 2023 – 2035” report to its list of offerings.
Several industry players and academic / research institutes across the world are investigating different types of allogeneic cell therapies (such as stem cell therapies, T-cell therapies, natural killer cell therapies and dendritic cell therapies) to treat a multitude of indications. Further, advancements in gene editing technologies, cell manufacturing techniques and genetic engineering tools have significantly contributed to the progress in this domain, by enhancing their therapeutic potential and reducing the risk of immune rejection.
To order this 220+ page report, which features 145+ figures and 135+ tables, please visit this link
Around 70% of the aforementioned therapies are being evaluated in early stages of development (phase I and phase II). It is worth mentioning that 40% of these therapies are derived from peripheral blood, followed by those derived from umbilical cord (19%). Further, most (86%) of the pipeline candidates are being evaluated as monotherapies, followed by those developed in combination with other therapeutic agents (14%).
Majority of the agreements related to allogeneic cell therapies were observed to be research and development agreements, representing around 25% of the total partnerships inked in this industry. Further, most of the intercontinental, as well as intracontinental deals have been inked by players based in North America.
Most of the funding amount (70%) was raised in 2020 and 2021. It is worth highlighting that majority of the amount in this domain has been raised through venture capital funding. It is important to note that more than 190 investors have actively financed projects / initiatives in this domain.
The investigation of allogeneic cell therapies has gained significant traction from various industry as well as non-industry players. Around 90% of the clinical trials in this domain are currently active. Further, more than 50% of the trials are in Phase I, enrolling around 7,450 patients.
Currently, majority share (~90%) of the overall allogeneic cell therapy market is captured by stem cell therapies; this trend is unlikely to change in the foreseen future as well. Further, by 2035, more than 45% of the market share is likely to be captured by allogeneic cell therapies derived from bone marrow / bone matrix. In terms of therapeutic area, allogeneic cell therapies being developed for post-transplant infections are expected to dominate the market, by 2035.
To request a sample copy / brochure of this report, please visit this link
The financial opportunity within the allogeneic cell therapy market has been analyzed across the following segments:
The report also features inputs from eminent industry stakeholders, according to whom, the availability of innovative technology platforms, lucrative funding and encouraging clinical trial results is likely to drive the growth of the overall allogeneic cell therapy market, in the foreseen future. The report includes detailed transcripts of discussions held with the following experts:
For additional details, please visit https://www.rootsanalysis.com/reports/allogeneic-cell-therapy-market.html or email sales@rootsanalysis.com
Contact:
Gaurav Chaudhary
+1 (415) 800 3415
+44 (122) 391 1091
Gaurav.chaudhary@rootsanalysis.com
MEDIA CITATIONS
We are your partners with no equity
We fit in your budget
We love what we do
Chance to prove ourselves
Best in class quality of work
Most trusted consulting partner in the industry
SUBSCRIBE TO INDUSTRY UPDATES
.png)
